You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Enhanced bioscavenger for medical countermeasures against organophosphorus agents

    SBC: Luna Innovations Incorporated            Topic: NIEHS

    DESCRIPTION (provided by applicant): Counteracting the threat of intoxication by organophosphorus nerve agents (OP's) is an important mission for homeland security as well as for treating workers exposed to pesticides. OP's act on acetylcholinesterase to prevent synaptic inactivation, thereby leading to immobilization and death on sustained application. Currently, the most promising stra ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. In-situ, real-time oxygen sensor to monitor the long-term efficacy of aerobicall

    SBC: ChromoSense LLC            Topic: NIEHS

    DESCRIPTION (provided by applicant): Groundwater and soil contamination has been associated with higher incidence of birth defects and cancer. Monitored natural attenuation of contaminants via biodegradation has proven effective in lowering contaminant levels, but these processes depend critically on dissolved oxygen levels. This project proposes to develop a robust oxygen sensor compound with che ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. A Thermo-responsive Biopharmaceutical to Enhance the Tear Production of Lacritin

    SBC: EYERX RESEARCH, INC.            Topic: NEI

    Project Summary/Abstract Ocular pharmaceuticals predominantly use the topical route of administration, which involves a number of benefits and limitations when compared to systemic drug routes. A major limitation of the ocular topical route is the rapid loss of drug via tearing and nasolacrimal drainage, requiring the use of frequent dosing and high drug concentrations that then create formulation ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Zonular Capture Accommodative-Disaccommodative Intraocular Lens System

    SBC: Z Lens LLC            Topic: NEI

    DESCRIPTION (provided by applicant): We are developing an accommodative - disaccommodative intraocular lens implant (ADIOL) system based on a novel concept of capturing zonular tension and transmitting it unimpeded to a dynamically position intraocular lens system. This is made possible by a zonular capture haptic (ZCH) apparatus. This apparatus lends itself equally well to several possible combin ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Nanoparticle scavengers for medical countermeasures against mycotoxin

    SBC: Luna Innovations Incorporated            Topic: NIGMS

    DESCRIPTION (provided by applicant): Mycotoxin is naturally occurring and is a toxic small molecule produced by fungi. These fungal toxins are representative of a large number of lipophilic agents that pose significant acute and chronic dangers to militarycombatants as potential warfare agents. There are many examples of mycotoxins, some more acutely potent than others. Mycotoxin is classified as ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema

    SBC: Covenant Therapeutics LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this proposal is to exploit a newly discovered anti-inflammatory function involving the aminopeptidase activity of the leukotriene A4 hydrolase for the treatment of pulmonary emphysema. The leukotrieneA4 hydrolase is a dual-functioning enzyme with dichotomously opposing functions. As an epoxide hydrolase, it catalyzes the conversion of leukotri ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters

    SBC: Noom, Inc.            Topic: NIMH

    DESCRIPTION (provided by applicant): Bulimia nervosa and binge eating disorder are marked by significant levels of impairment and psychiatric comorbidity, affecting approximately 5-7% of the US population. Guided self-help cognitive behavioral (CBT-GSH) therapy has been show to be an effective treatment to reduce binge eating for patient with both disorders. However, there is limited uptake among ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Remote focusing through spatial light modulation for multifocal multiphoton micro

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent

    SBC: PHOTOLITEC LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Photolitec's patented technology is focused on developing improved agents for tumor- imaging, image-guided surgery and/or photodynamic therapy (PDT). The proposed STTR proposal includes fluorescence-image guided PDT, aSee and Treat approach. The fluorescence imaging compound with long wavelength absorption near 800 nm should be extremely useful for image ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government